Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Berges

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Der Urologe. Ausg. A|November 13, 2002
[Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results]M Oelke, K Höfner, R R Berges, et al.
Der Urologe. Ausg. A|March 19, 2013
[UroLift®: an operative non-ablative procedure for treatment of benign prostatic syndrome]R Berges, K D Sievert, C Gratzke, et al.
Lancet (London, England)|June 17, 1995
Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study GroupR R Berges, J Windeler, H J Trampisch, et al.
Urology|November 20, 2003
Prostate size and PSA serum levels in male patients with spinal cord injuryJürgen Pannek, Richard R Berges, Goetz Cubick, et al.
European Urology|July 21, 2001
Male lower urinary tract symptoms and related health care seeking in GermanyR R Berges, L Pientka, K Höfner, et al.
European Urology|January 1, 1996
Cyproterone acetate in the treatment of advanced prostatic cancer: retrospective analysis of liver toxicity in the long-term follow-up of 89 patientsA Hinkel, R R Berges, J Pannek, et al.
International Journal of Clinical Practice|July 2, 2011
Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse eventsV Mirone, A Sessa, F Giuliano, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1993
Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablationR R Berges, Y Furuya, L Remington, et al.
Journal of Andrology|November 1, 1992
Androgen regulation of programmed death of normal and malignant prostatic cellsJ T Isaacs, P I Lundmo, R Berges, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Cell turnover in human seminal vesicles and the prostate: an immunohistochemical studyJ Pannek, R R Berges, J Sauvageot, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Der Urologe. Ausg. A|November 13, 2002
[Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results]M Oelke, K Höfner, R R Berges, et al.
Der Urologe. Ausg. A|March 19, 2013
[UroLift®: an operative non-ablative procedure for treatment of benign prostatic syndrome]R Berges, K D Sievert, C Gratzke, et al.
Lancet (London, England)|June 17, 1995
Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study GroupR R Berges, J Windeler, H J Trampisch, et al.
Urology|November 20, 2003
Prostate size and PSA serum levels in male patients with spinal cord injuryJürgen Pannek, Richard R Berges, Goetz Cubick, et al.
European Urology|July 21, 2001
Male lower urinary tract symptoms and related health care seeking in GermanyR R Berges, L Pientka, K Höfner, et al.
European Urology|January 1, 1996
Cyproterone acetate in the treatment of advanced prostatic cancer: retrospective analysis of liver toxicity in the long-term follow-up of 89 patientsA Hinkel, R R Berges, J Pannek, et al.
International Journal of Clinical Practice|July 2, 2011
Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse eventsV Mirone, A Sessa, F Giuliano, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1993
Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablationR R Berges, Y Furuya, L Remington, et al.
Journal of Andrology|November 1, 1992
Androgen regulation of programmed death of normal and malignant prostatic cellsJ T Isaacs, P I Lundmo, R Berges, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Cell turnover in human seminal vesicles and the prostate: an immunohistochemical studyJ Pannek, R R Berges, J Sauvageot, et al.
Pageof 4